Cite
HARVARD Citation
Tanzawa, S. et al. (2022). Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study). Therapeutic advances in medical oncology. p. . [Online].